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Funded by the Centers for Disease Control and
Prevention.
This supplement to CANCER was supported by
Cooperative Agreement Number U50 DP42407104 from the Centers for Disease Control and Prevention (CDC).
Dr. Ahmed was formerly with the Division of Cancer Prevention and Control at the Centers for
Disease Control and Prevention, Atlanta, Georgia.
The following registries, which cover approximately 83% of the US population, contributed
data to the production of this supplement:
Alaska, Alabama, Arkansas, California, Colorado,
Connecticut, District of Columbia, Delaware, Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas,
Kentucky, Louisiana, Maine, Massachusetts,
Michigan, Minnesota, Missouri, Montana,
Nebraska, New Jersey, New Mexico, New York,
Ohio, Oklahoma, Oregon, Pennsylvania, Rhode
Island, South Carolina, Texas, Utah, Vermont,
Washington, West Virginia, and Wisconsin.

T

his supplement, known as the ABHACUS (Assessing the Burden
of HPV-Associated Cancers in the United States) supplement,
contains 22 articles. Together, these articles provide a comprehensive snapshot of data related to the occurrence and control of multiple cancers that have been associated with the human
papillomavirus (HPV). These analyses highlight the burden of HPVassociated cancers in the US population as a whole and among vulnerable population subgroups. We anticipate that these findings will
be an important resource for enhancing existing strategies for the
prevention and control of HPV-associated cancers.
HPV is estimated to be responsible for 5.2% of the cancers diagnosed worldwide.1 Virtually 100% of cervical cancers are causally
associated with HPV, and there is increasing evidence of the role
that HPV plays in other anogenital cancers and oropharyngeal cancers. With the recent approval and recommendation of an HPV vaccine that contains HPV–16 and HPV–18, interest in quantifying the
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spectrum and burden of cancers is heightened. The
International Agency for Research on Cancer (IARC)
has determined that there is sufficient evidence for
the carcinogenicity of HPV–16 in the cervix, vulva,
vagina, penis, anus, oral cavity, and oropharynx.2
The IARC has found sufficient evidence of the role
HPV–18 plays in cervical cancer, with limited or no
evidence in other sites. Together, cervical cancer
combined with the other HPV-associated cancers
potentially afflicts an additional 25,000 persons every
year in the US.
Worldwide and in the US, the excitement and
concern surrounding the HPV vaccine has been profound. The excitement derives from the potential of
the vaccine to reduce the burden of cervical cancer
in countries that have no screening infrastructure as
well as in countries such as the US, in which nearly
11,000 women each year are told they have invasive
cervical cancer and 4000 die from this disease, despite the availability of screening. The HPV vaccine
also has the potential to impact a significant proportion of other cancers for which there typically is no
routine screening. Conversely, the concern is that
vaccine recipients may not continue to undergo
screening for cervical cancer. Yet another concern is
that if vaccine uptake is lower in those groups at
highest risk of developing cervical cancer, current
racial/ethnic or geographic disparities could increase.
We hope that the articles in this supplement will
highlight the burden and disparities associated with
these cancers before vaccine implementation.
This supplement includes an in-depth analysis of
cancer incidence and mortality data from population-based central cancer registries that house highquality data. Fourteen articles are based mainly on
cancer occurrence, using incidence data from population-based central cancer registries that participate
in the Centers for Disease Control and Prevention
(CDC)’s National Program of Cancer Registries
(NPCR) and/or the National Cancer Institute (NCI)’s
Surveillance, Epidemiology, and End Results (SEER)
program. The NPCR program, which was established
through the Cancer Registries Amendment Act
passed by the US Congress in 1992, began providing
financial support and technical assistance to population-based central cancer registries in 1994. This program currently supports central registries in 45
states, the District of Columbia, and 3 US territories;
these registries cover approximately 96% of the US
population. The SEER program, which was established as a result of the National Cancer Act of 1971,
currently supports 14 such registries and 3 supplemental registries, covering approximately 26% of the
US population. The population-based central cancer

registries collect information on all reportable cancer cases within a state or another defined geographic area. Today, the NPCR and SEER programs
together cover 100% of the US population, and data
regarding more than 1 million new invasive cancer
cases are added each year. Medical records are the
primary source of the data. Both the NPCR and
SEER data are collected and reported with the use of
uniform data items and codes, as documented by
the North American Association of Central Cancer
Registries.3 The Institute of Medicine has recognized
the importance of these 2 programs as valuable
resources for studies on cancer.4
National and regional population coverage of
cancer registry data has been achieved only within
the last few years. Such coverage now allows for the
unprecedented examination of rare cancers, as well
as a focus on cancer burden by age, sex, race, histology, geography, and other variables. This supplement
leverages US population-based cancer registries by
demonstrating the current burden of disease for all 6
HPV-associated cancers in each of the individual
site-specific chapters (cervical, vaginal, vulvar, anal,
penile, and oropharyngeal cancers).5–10 Before engaging in any analyses, the steering committee spent a
considerable amount of time establishing common
definitions. Watson et al describe the registries in
more detail and provide some standardized analytic
criteria used in the site-specific analyses.11 Benard
et al highlight some of the applications of cancer registry data, augmented with linked census-based
socioeconomic data, thereby to our knowledge
underscoring for the first time general patterns that
are observed for each of the HPV-associated cancers.12 Ryerson et al focus on the HPV-associated
cancer burden for oral cavity and oropharyngeal cancers, using anatomic subsites as a proxy for HPV
association.5
Several articles take advantage of the unique
attributes of certain central cancer registries or go
beyond the description of cancer occurrence. For
example, data from the California Cancer Registry
allow for the computation of cancer incidence rates
for Asian subpopulations, some of which have been
known to have the highest incidence of cervical cancer in the US.13 Despite the 1996 recommendation to
discontinue the collection of data regarding carcinoma in situ (CIS) of the cervix, the Michigan Cancer
Surveillance System continued to collect these data;
Copeland et al present current trends related to cervical CIS.14 Hopehayn et al and Coughlin et al examine the burden of cervical cancer in areas with
disproportionate burdens: Appalachia and those
states bordering Mexico.15,16 Additional articles use
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cancer registry data to examine treatment patterns
for female HPV-associated cancers and the risk of
other HPV-associated cancers among cervical cancer
survivors.17 Finally, an examination of the years of
potential life lost and mortality-related productivity
costs of all HPV-associated cancers is presented.18
Because of the importance of primary prevention
and screening for cancer control, another aim of this
supplement is to update the reader with pertinent information related to vaccination and screening.
Dunne et al describe the epidemiology of HPV and
the HPV vaccine.19 Tiro et al examine various
national behavioral surveillance systems related to
cervical cancer screening and vaccination.20 Castle
et al comment on the potential impact of the HPV
vaccine on cervical cancer screening in the years to
come.21 Whiteside et al present an overview of what
is known concerning the molecular mechanisms
involved in HPV oncogenesis to help readers interpret data regarding HPV causality in noncervical cancers and understand the new molecular markers
proposed for screening.22 Gillison et al discuss the
role of HPV in noncervical cancers and apply worldwide and US estimates of attributable fractions to
further define the burden of HPV-associated cancers.22 Another article comments on the role the cancer registries can play in monitoring the impact of
the HPV vaccine.23 Lastly, Khan et al describe 2 key
CDC programs related to cervical cancer prevention
(the Vaccines for Children Program) and screening
(the National Breast and Cervical Cancer Early
Detection Program) that target uninsured individuals
and other vulnerable populations.24
A few years ago, the National Coordinating
Council for Cancer Surveillance developed a national
framework for cancer surveillance in the US.25 This
supplement represents the application of this cancer
surveillance framework to HPV-associated cancers.
To be effective, cancer surveillance requires coordination and cooperation among government, professional, nonprofit, and private organizations, and the
articles contained in this supplement demonstrate
the success that can be achieved through such collective efforts. Greater than 100 investigators and 30
peer reviewers from various divisions at the CDC,
various parts of the NCI, population-based cancer
registries (Arkansas, Arizona, California, Florida,
Idaho, Illinois, Kansas, Kentucky, Louisiana, Maine,
Michigan, New Mexico, New York, South Dakota,
Tennessee, Texas, and Washington DC), academic
institutions, and the American Cancer Society
worked diligently and collaboratively over the past
year and a half to produce this supplement. We wish
to express our deepest gratitude to them.
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